Neurocrine Biosciences, Inc. (NBIX) Director Sells $855,000.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director William H. Rastetter sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $90.00, for a total transaction of $855,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded up $1.96 during mid-day trading on Friday, reaching $88.87. The company’s stock had a trading volume of 760,422 shares, compared to its average volume of 1,158,821. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. The stock has a market cap of $7,800.00, a price-to-earnings ratio of -40.03, a P/E/G ratio of 83.00 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $38.98 and a 12 month high of $90.10.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter in the previous year, the business posted ($0.43) EPS. equities research analysts predict that Neurocrine Biosciences, Inc. will post -1.57 earnings per share for the current year.

A number of research analysts have recently issued reports on the company. Jefferies Group reiterated a “buy” rating and set a $69.00 target price (up previously from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. BMO Capital Markets reiterated an “outperform” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. Leerink Swann reiterated an “outperform” rating and set a $72.00 target price (up previously from $67.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 10th. Piper Jaffray Companies reiterated a “buy” rating and set a $76.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. Finally, Citigroup reiterated a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $82.31.

A number of hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its holdings in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock valued at $7,380,000 after purchasing an additional 810 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in Neurocrine Biosciences by 0.9% in the 3rd quarter. Mutual of America Capital Management LLC now owns 112,862 shares of the company’s stock valued at $6,916,000 after purchasing an additional 1,036 shares in the last quarter. Grandfield & Dodd LLC lifted its holdings in Neurocrine Biosciences by 24.1% in the 3rd quarter. Grandfield & Dodd LLC now owns 7,610 shares of the company’s stock valued at $466,000 after purchasing an additional 1,480 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Neurocrine Biosciences by 51.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,704 shares of the company’s stock valued at $288,000 after purchasing an additional 1,599 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/26/neurocrine-biosciences-inc-nbix-director-sells-855000-00-in-stock.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit